These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2110438)

  • 1. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1990 Mar; 34(3):487-8. PubMed ID: 2110438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1403-5. PubMed ID: 3118798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.
    Bustamante CI; Wharton RC; Wade JC
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1814-5. PubMed ID: 2126693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].
    Prévotat A; Leroy S; Perez T; Wallet F; Wallaert B
    Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
    Ma W; Li J; Wang D; Yu C; Sun S
    Lett Appl Microbiol; 2019 Sep; 69(3):198-203. PubMed ID: 31236975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series.
    Spoletini G; Etherington C; Shaw N; Clifton IJ; Denton M; Whitaker P; Peckham DG
    J Antimicrob Chemother; 2019 May; 74(5):1425-1429. PubMed ID: 30649419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics.
    Bosso JA; Allen JE; Matsen JM
    Antimicrob Agents Chemother; 1989 Apr; 33(4):526-8. PubMed ID: 2499252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.
    Klinger JD; Aronoff SC
    J Antimicrob Chemother; 1985 Jun; 15(6):679-84. PubMed ID: 3161856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.
    Figueredo VM; Neu HC
    J Antimicrob Chemother; 1988 Jul; 22(1):41-50. PubMed ID: 3139615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
    Allen JE; Bosso JA; Saxon BA; Matsen JM
    Diagn Microbiol Infect Dis; 1987 Sep; 8(1):51-5. PubMed ID: 3126018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group.
    Richard DA; Nousia-Arvanitakis S; Sollich V; Hampel BJ; Sommerauer B; Schaad UB
    Pediatr Infect Dis J; 1997 Jun; 16(6):572-8. PubMed ID: 9194107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.
    Mularoni A; Mezzatesta ML; Pilato M; Medaglia AA; Cervo A; Bongiorno D; Aprile A; Luca A; Stefani S; Grossi P
    Int J Infect Dis; 2021 Jul; 108():510-512. PubMed ID: 34091004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.
    Schaad UB; Wedgwood-Krucko J; Guenin K; Buehlmann U; Kraemer R
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):858-65. PubMed ID: 2512129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
    McGrath BJ; Bailey EM; Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2741-6. PubMed ID: 1482142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K; Lapointe JR
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.